1. Home
  2. INMB vs BSEM Comparison

INMB vs BSEM Comparison

Compare INMB & BSEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo INmune Bio Inc.

INMB

INmune Bio Inc.

HOLD

Current Price

$2.44

Market Cap

64.7M

Sector

Health Care

ML Signal

HOLD

BSEM

BioStem Technologies Inc. Common Stock

N/A

Current Price

$3.71

Market Cap

59.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
INMB
BSEM
Founded
2015
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
64.7M
59.6M
IPO Year
2018
2026

Fundamental Metrics

Financial Performance
Metric
INMB
BSEM
Price
$2.44
$3.71
Analyst Decision
Buy
Analyst Count
5
0
Target Price
$5.40
N/A
AVG Volume (30 Days)
339.7K
114.1K
Earning Date
05-07-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
11.85
N/A
EPS
N/A
N/A
Revenue
$50,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
257.14
N/A
52 Week Low
$1.09
$2.25
52 Week High
$2.50
$4.66

Technical Indicators

Market Signals
Indicator
INMB
BSEM
Relative Strength Index (RSI) 58.65 46.76
Support Level $1.16 $2.25
Resistance Level $2.50 $4.02
Average True Range (ATR) 0.12 0.33
MACD -0.01 0.03
Stochastic Oscillator 52.51 70.01

Price Performance

Historical Comparison
INMB
BSEM

About INMB INmune Bio Inc.

INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.

About BSEM BioStem Technologies Inc. Common Stock

BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.

Share on Social Networks: